Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-30
DOI
10.1038/s41416-019-0573-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Case Report: Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
- (2019) Xiaofei Wang et al. Journal of Thoracic Oncology
- On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation
- (2019) Benjamin P Brown et al. CLINICAL CANCER RESEARCH
- Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
- (2019) Ayesha Murtuza et al. CANCER RESEARCH
- 114OPotential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study
- (2019) C Xu et al. ANNALS OF ONCOLOGY
- A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.
- (2019) Jonathan Daniel Schoenfeld et al. JOURNAL OF CLINICAL ONCOLOGY
- Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
- (2019) Silvia La Monica et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Single and dual targeting of mutant EGFR with an allosteric inhibitor
- (2019) Ciric To et al. Cancer Discovery
- Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
- (2018) C Ricordel et al. ANNALS OF ONCOLOGY
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
- (2018) G.M. O’Kane et al. Current Oncology
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
- (2018) Jin Kang et al. Journal of Thoracic Oncology
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR -Mutated NSCLC
- (2018) Roberta Minari et al. Journal of Thoracic Oncology
- GOPC - ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
- (2018) Liang Zeng et al. Journal of Thoracic Oncology
- EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
- (2018) Qi Zhang et al. Journal of Thoracic Oncology
- Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib
- (2018) Yutao Liu et al. LUNG CANCER
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
- (2018) R. Minari et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
- (2018) Chia-Chi Lin et al. Lancet Respiratory Medicine
- Taking advantage of drug resistance, a new approach in the war on cancer
- (2018) Liqin Wang et al. Frontiers of Medicine
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.
- (2018) Zofia Piotrowska et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.
- (2018) Morihito Okada et al. JOURNAL OF CLINICAL ONCOLOGY
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
- (2018) Atsushi Nakamura et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition
- (2018) Lei Deng et al. Journal of Thoracic Oncology
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
- (2018) Chien-Hui Weng et al. ONCOGENE
- Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
- (2018) Zachary A. Yochum et al. ONCOGENE
- Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
- (2018) Jing Zhao et al. OncoTargets and Therapy
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
- (2018) Tao Jiang et al. Journal of Thoracic Disease
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- 1429PMolecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients
- (2018) M H Hong et al. ANNALS OF ONCOLOGY
- LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
- (2018) V A Papadimitrakopoulou et al. ANNALS OF ONCOLOGY
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies
- (2018) Myung-Ju Ahn et al. CANCER
- Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
- (2018) Yan Zhang et al. OncoTargets and Therapy
- Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
- (2018) Jana Fassunke et al. Nature Communications
- Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
- (2018) Sha Zhao et al. LUNG CANCER
- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
- (2017) Silvia La Monica et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
- (2017) Zhen Wang et al. Journal of Thoracic Oncology
- Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer
- (2017) Nir Peled et al. Journal of Thoracic Oncology
- Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer
- (2017) Emily R. York et al. Journal of Thoracic Oncology
- Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
- (2017) Chao-Chi Ho et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
- (2017) A. Oztan et al. LUNG CANCER
- Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
- (2017) Franciele H. Knebel et al. LUNG CANCER
- Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- Tumor Evolution as a Therapeutic Target
- (2017) Nabil Amirouchene-Angelozzi et al. Cancer Discovery
- Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
- (2017) Shoko Noda-Narita et al. Translational Cancer Research
- Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
- (2017) Tristan A. Barnes et al. Frontiers in Oncology
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
- (2016) P. Ballard et al. CLINICAL CANCER RESEARCH
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy
- (2016) H. Tang et al. EMBO Molecular Medicine
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay
- (2016) Roopika Menon et al. Journal of Thoracic Oncology
- Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
- (2016) Jun Soo Ham et al. Journal of Thoracic Oncology
- L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC
- (2016) Melissa Bersanelli et al. Journal of Thoracic Oncology
- S768I Mutation in EGFR in Patients with Lung Cancer
- (2016) Konstantinos Leventakos et al. Journal of Thoracic Oncology
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
- (2016) Yaqiong Tian et al. ONCOLOGY RESEARCH
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- (2015) D. Ercan et al. CLINICAL CANCER RESEARCH
- Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
- (2015) Julian Engel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
- (2015) Juliana Eng et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Resistance to AZD9291
- (2015) Tae Min Kim et al. Journal of Thoracic Oncology
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
- (2010) S. Heon et al. CLINICAL CANCER RESEARCH
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now